Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Other material
confidence 75%
filed 2026-06-17
Item 8.01
uniQure announced its plan to submit a BLA for AMT-130 in Huntington's Disease in Q3 2026, following FDA Type B meeting feedback that the 3-year Phase I/II data would be acceptable for accelerated approval. This is a material regulatory milestone for a gene therapy company, but does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M&A, impairment, or litigation). The disclosure is material to investors as it signals significant progress toward a potential regulatory approval pathway, though the event is contingent on future FDA alignment and BLA submission.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 8.01
Verastem announced positive updated results from the RAMP 205 Phase 1b/2a clinical trial evaluating avutometinib plus defactinib in combination with chemotherapy for metastatic pancreatic cancer, with an 86% overall survival rate at 6 months, 68% progression-free survival rate, and 52% objective response rate. The company also announced initiation of dosing in the TARGET-D 201 Phase 2 registration-directed trial for VS-7375.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-17
Item 1.01
Enterprise Financial Services Corp completed a $175 million issuance of subordinated notes on June 17, 2026, pursuant to a registered offering under Form S-3, creating material direct financial obligations and expanding the company's capital structure.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 3.03
The registrant adopted a First Amended and Restated Certificate of Incorporation and Bylaws in connection with the business combination closing, materially modifying the rights of Class A stockholders.
View raw filing on EDGAR →
8-K
Other material
confidence 55%
filed 2026-06-17
Item 1.02
Plains GP Holdings terminated two material credit facilities (the Existing Revolving Credit Agreement and the Hedged Inventory Facility) and closed a new Revolving Credit Agreement, representing a routine refinancing of its credit arrangements.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 8.01
Southern Copper priced a $1.25 billion senior unsecured notes offering at 5.350% due 2036. While this is a material debt issuance that would affect investor assessment of the company's capital structure and financing activities, it does not fit cleanly into the more specific event categories (it is not a dilutive equity issuance, M&A activity, or other defined event type). The disclosure of a substantial debt offering under Item 8.01 warrants classification as a material event outside the standard taxonomy.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 1.02
South Plains Financial terminated a Board Representation Agreement with Henry TAW LP, a shareholder that originally owned approximately 16% and now owns less than 10% of outstanding shares. The termination reflects the Company's maturation as a public entity and shift toward a broader shareholder base.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 8.01
South Plains Financial entered into a stock repurchase agreement with retiring CEO Curtis C. Griffith to repurchase 300,000 shares at fair market value, approved by the board with Griffith recused. The repurchase is a related-party transaction tied to his retirement.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-17
Item 2.03
CarMax entered into a $500 million term loan credit agreement with MUFG Bank on June 15, 2026, establishing a three-year term facility with customary covenants and interest terms.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 7.01
The disclosure announces completion of target enrollment in a Phase 2b clinical trial (MIST trial) for AP01, a lead product candidate. While this is a material clinical development milestone that would affect investor assessment of the company's pipeline progress and de-risking, it does not fit neatly into the standard taxonomy categories. The event is disclosed under Item 7.01 (Regulation FD Disclosure) rather than a dedicated Item, and represents clinical trial progress rather than earnings, M&A, executive changes, or other specifically enumerated event types.
View raw filing on EDGAR →
8-K
Other material
confidence 35%
filed 2026-06-17
Item 8.01
The filing discloses a press release under Item 8.01 (Other Events) but provides no substantive detail about the content or nature of the announcement. Without access to Exhibit 99.1, the specific event cannot be determined. Given Verizon's size and the formal 8-K filing, the press release likely addresses a material matter, but the event type cannot be confidently classified without knowing its subject matter.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-17
Item 5.03
Smartbird amended its Certificate of Incorporation and Bylaws to change the company name to Smartbird, Inc., remove public benefit corporation status, and lower the stockholder quorum requirement from a majority to one-third, representing material governance and structural changes.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 5.03
Allurion Technologies implemented a 1-for-15 reverse stock split, approved by stockholders at the December 2025 Annual Meeting, with the Charter Amendment filed on June 12, 2026 and effective June 17-18, 2026. This material corporate action affects the company's share structure, trading symbol, and terms of warrants and convertible securities.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 8.01
The Company resubmitted a New Drug Application (NDA) to the FDA for relacorilant, a treatment for Cushing's syndrome. This is a material regulatory milestone for a biopharmaceutical company, as NDA resubmission represents progress toward potential commercialization of a key product candidate. However, it does not fit neatly into the more specific event categories (e.g., it is not an earnings release, M&A activity, or executive change), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 1.01
The Company entered into a Third Amended and Restated Operating Agreement on June 15, 2026, which amended the operating agreement to reflect the liquidation and dissolution of Series I and updated indemnification provisions. This represents a material structural change to the Company's organizational documents and governance framework.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 5.03
Lakewood-Amedex Biotherapeutics approved and implemented a 1-for-10 reverse stock split, effective June 19, 2026, which was filed with the Nevada Secretary of State. This structural capital event materially modifies the rights of security holders by reducing share count and affecting trading mechanics and investor holdings.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-17
Item 2.03
ISQ Open Infrastructure entered into a $60 million revolving credit facility (expandable to $180 million) on June 11, 2026, creating a direct financial obligation with customary covenants and events of default.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 8.01
Faraday Future announced a major product launch on June 16, 2026, including unveiling its "full-form EAI Robot World spanning six product series," launching a "Three-in-One EAI robotics education ecosystem strategy," and debuting an "All-New Futurist humanoid robot and FX Navi with pricing starting at $1,990." This represents a significant business development and product diversification announcement that would materially affect investor assessment of the company's strategic direction and revenue prospects, but does not fit neatly into the more specific event categories (not an earnings release, M&A activity, impairment, or other defined event type).
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-17
Item 8.01
This Item 8.01 discloses the completion and post-closing mechanics of an IPO (20 million units at $10/unit generating $200M gross proceeds), a concurrent private placement ($2.1M), partial exercise of an over-allotment option (1.65M units, $16.5M), and placement of $216.5M in trust. While IPO completion is material, the disclosure is primarily administrative detail about capital raised and trust account mechanics rather than a discrete earnings release, M&A event, or other specific taxonomy event. The filing reports "as previously reported" events, suggesting this is a follow-up disclosure of already-announced transactions.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 8.01
The disclosure announces a 1-for-20 reverse share split effective July 1, 2026, for the 2x Long VIX Futures ETF (UVIX). While reverse splits are structural corporate actions that affect share price and outstanding share count, this event does not fit neatly into the delisting_risk category (no delisting threat is mentioned) nor any other specific taxonomy category. The action is material to shareholders as it affects NAV per share, share count, and potential tax consequences from fractional share redemptions, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Myseum.AI announced signing a non-binding letter of intent with Scanon.ai Systems to explore a collaborative development partnership involving integration of AI and computer vision capabilities into the Company's Picture Party platform, with potential reciprocal revenue sharing and participation in Scanon's financing round. While this represents a material strategic partnership announcement, it does not fit cleanly into the M&A taxonomy (no acquisition, merger, or change of control is disclosed—only a non-binding LOI for collaboration), nor does it constitute a standard earnings release, executive change, or other enumerated event type. The disclosure would affect a reasonable investor's assessment of the Company's strategic direction and product roadmap.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 7.01
The Board unanimously approved submitting governance proposals to stockholders to eliminate the classified board structure and all supermajority voting provisions in the Articles of Incorporation. This represents a material change to corporate governance structure that would affect shareholder voting rights and director election processes. While not fitting neatly into the specific event categories (it is not a shareholder vote result, but rather a proposal for one), the elimination of classified boards and supermajority voting provisions is material to investors' assessment of governance and control dynamics.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 1.01
AXT's subsidiary Tongmei entered into a long-term supply agreement with Casela committing Casela to purchase approximately $25.4 million of InP wafer substrates during 2027, with 50% prepayment required within 15 business days. While this is a material commercial contract (Item 1.01), it is fundamentally a supply/customer agreement rather than a merger, acquisition, disposition, or change of control. The agreement secures significant committed revenue and prepayment but does not fit the specific M&A taxonomy categories, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 8.01
The Company extended the expiration date of a rights offering from June 23 to June 29, 2026, at a subscription price of $6.90 per share. While this is a material capital-raising event affecting shareholder dilution and the Company's financing timeline, it does not fit neatly into the more specific categories (dilutive_issuance typically covers the initial announcement of an unregistered equity sale, not an extension of an existing offering). The extension itself is material to investors tracking the offering's progress and their subscription decision window.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 7.01
The filing discloses a "strategic investment in Skyline Instruments Corporation" announced via press release on June 17, 2026. While the prose does not specify the investment amount, structure, or whether it constitutes a material acquisition under Item 1.01, a strategic investment by a public company is typically material to investors assessing the registrant's capital allocation and business strategy. The disclosure does not fit the more specific categories (ma_activity would require clearer language about acquisition/merger/change of control; dilutive_issuance would require equity issuance detail). Classified as other_material pending fuller details in the attached exhibit.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-17
Item 8.01
The disclosure announces a Board declaration of an annual cash dividend of $0.55 per share with specific payment and record dates. While dividend declarations are routine corporate actions, this is material to shareholders as it affects their investment returns and the company's capital allocation. However, it does not fit neatly into the more specific event categories (not earnings, not executive-related, not M&A, not a restatement or going-concern issue), so "other_material" is the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
MIRA Pharmaceuticals disclosed submission of a Phase 2a clinical trial protocol to the FDA for Ketamir-2, a proprietary oral NMDA receptor modulator for chemotherapy-induced peripheral neuropathy, with FDA acknowledgment of receipt. This represents a material clinical development milestone for a pharmaceutical company, but does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M&A activity, impairment, or other defined event types). The advancement of a lead drug candidate through FDA regulatory stages is material to investors assessing the company's pipeline and prospects.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Eva Live Inc. announced the formation of its first wholly owned subsidiary, Eva Defense Inc., described as a "strategic initiative designed to pursue acquisitions and partnerships within the rapidly growing drone, autonomous systems, and defense technology sectors." While this is a corporate restructuring event involving the creation of a subsidiary for M&A purposes, it does not constitute a completed acquisition, disposition, merger, or change of control (which would trigger ma_activity). The disclosure is material as it signals a strategic pivot and capital allocation toward a new business segment, but the event itself—subsidiary formation—does not fit cleanly into the more specific event categories.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
The filing discloses cancellation of 7.1 million pre-funded warrants pending a legal investigation into suspected misconduct including collusion, beneficial ownership cap violations, use of foreign nominees, and transfer agent discrepancies. While this involves warrant cancellation and regulatory/legal concerns, it does not fit neatly into the specific categories (not a litigation disclosure per se, not a covenant breach, not a delisting notice). The material nature of the investigation and warrant cancellation warrants classification as a material event outside the standard taxonomy.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 8.01
The disclosure announces preliminary clinical observations supporting evaluation of ELI-002 7P in combination with checkpoint inhibition and plans for a Phase 1 study in metastatic KRAS pancreatic cancer. This is a material clinical development milestone for a biopharmaceutical company, but does not fit neatly into more specific event categories (not an earnings release, not a formal restatement, not an impairment). The clinical progress and future study plans would affect investor assessment of the company's pipeline and prospects.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 1.01
Kilroy Realty entered into a Fifth Amended and Restated Credit Agreement providing a $1.25 billion revolving credit facility (expandable to $1.7 billion) and an Amended and Restated Term Loan Agreement for a $250 million facility (expandable to $400 million) on June 12, 2026. These material refinancings and amendments to existing credit facilities affect the company's liquidity and financial flexibility but do not constitute a discrete M&A transaction, acquisition, disposition, or change of control.
View raw filing on EDGAR →
8-K
Other material
confidence 70%
filed 2026-06-17
Item 5.03
iQSTEL amended and restated the Certificate of Designation for Series B Preferred Stock, materially relaxing conversion rights to permit conversion at any time with only 5 days' notice (versus previously only at the end of a 12-month term with 60 days' notice) and adding accrued dividend payouts upon conversion, affecting the Company's capital structure and dilution risk profile.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-17
Item 1.01
The filing is captioned as Item 1.01 (Entry into a Material Definitive Agreement) and announces a "major project award" for subsea umbilical services. However, the disclosure is sparse and does not clearly establish whether this constitutes a material acquisition, disposition, or change of control (the core M&A events under Item 1.01). The language "award of a major project" suggests a significant contract or service engagement rather than a traditional M&A transaction, making the classification ambiguous. Given the materiality to the company but the lack of clarity on the specific nature of the agreement, "other_material" is the most defensible classification pending review of the full press release.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 8.01
AbCellera announced a preclinical research collaboration and option/license agreement for T-cell engaging multispecific antibodies targeting GI cancers and solid tumors. While this represents a material strategic partnership leveraging the company's core antibody discovery platform, it does not fit cleanly into more specific event categories (not an M&A transaction, not an earnings release, not an executive change). The disclosure would affect a reasonable investor's assessment of the company's pipeline and strategic direction, warranting material classification under "other_material."
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 8.01
BitGo's board approved a $50 million share repurchase program, a material capital allocation decision that signals management confidence and affects shareholder value. While share repurchases are routine corporate actions, the $50 million authorization is material to investors assessing capital deployment strategy and cash management. This does not fit neatly into the more specific event categories (not an earnings release, M&A, impairment, or executive change), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
6-K
Other material
confidence 75%
filed 2026-06-17
EX-99.1
The exhibit discloses a 3-for-1 reverse stock split of Subordinate Voting Shares and concurrent consolidation of Multiple Voting Shares, effective June 5, 2026, reducing outstanding shares from ~699 million to ~233 million. While this is a material capital structure event affecting all shareholders, it does not fit neatly into the standard 8-K taxonomy (no M&A, no dilutive issuance, no debt, no governance appointment/departure). The reverse split is a material restructuring event that would affect investor assessment of share count and market capitalization, warranting classification as a material event outside the named categories.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 7.01
The filing discloses a corporate name change from Skillz Inc. to Firy Inc., effective June 18, 2026, along with presentation of an investor deck at the 2026 annual stockholder meeting. While a name change itself is typically administrative, the accompanying investor presentation reveals material strategic developments including a major acquisition (Beamable), significant revenue growth projections (revenue expected to more than double 2025–2028), and a substantial litigation settlement ($80M awarded, $420M–$1.4B+ potential recovery). The combination of rebranding, strategic repositioning, and material financial developments makes this a material event that would affect a reasonable investor's assessment of the company's direction and value, though it does not fit neatly into a single specific category.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 8.01
Mountain Crest announced the commencement of separate trading of ordinary shares and rights previously bundled in units, effective June 22, 2026, with new NASDAQ ticker symbols ("MCAH" and "MCAHR"). This is a material structural change affecting how the Company's securities trade and how investors can hold the underlying components, but it does not fit neatly into the more specific event categories (it is not an earnings release, executive change, M&A activity, impairment, or other defined event type). Classified as other_material because it is a material disclosure affecting the total mix of information available to investors regarding the Company's capital structure and trading mechanics.
View raw filing on EDGAR →
8-K
Other material
confidence 70%
filed 2026-06-17
Item 5.03
Flag Ship Acquisition Corp amended its Amended and Restated Memorandum and Articles of Association and its Investment Management Trust Agreement to extend the deadline for consummating a business combination from June 20, 2026 to June 20, 2027, with up to twelve one-month extensions contingent on sponsor funding. These governance amendments materially affect the SPAC's timeline and sponsor obligations but do not constitute a discrete M&A transaction.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 8.01
The filing discloses a postponement of an Extraordinary General Meeting and extension of the deadline to consummate an initial business combination from June 19, 2026 to October 19, 2026, along with amended proxy materials seeking shareholder approval. While this involves a shareholder vote, the core event is the material postponement and extension of the business combination deadline for a SPAC, which affects the timing and terms of the proposed transaction. This does not fit cleanly into shareholder_vote_results (which typically reports vote outcomes) but is material to investors as it materially alters the transaction timeline and requires shareholder approval of governing document amendments.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 8.01
The Trust discloses a material change in its distribution policy: it intends to make quarterly cash distributions of staking income to shareholders, with the first distribution expected in July 2026. This represents a significant operational and financial commitment that would affect investor returns and tax treatment. While the disclosure does not fit neatly into the standard taxonomy (it is neither an earnings release, executive change, M&A activity, nor a financial restatement), it is material to shareholders as it directly impacts the economic benefits of holding the shares and relies on specific IRS guidance (Revenue Procedure 2025-31) that could be modified or withdrawn.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-16
Item 8.01
Ford Motor Credit Company issued £300 million in senior notes (6.120% due 2032) under an effective S-3 registration statement. While this is a material debt issuance affecting the company's capital structure and financial obligations, it does not fit cleanly into the standard 8-K taxonomy—it is neither a covenant breach, going concern issue, nor a restatement. The disclosure is routine debt financing activity disclosed under Item 8.01 (Other Events), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 55%
filed 2026-06-16
Item 2.03
Air T, Inc. created a direct financial obligation through Amendment No. 6 to the Alerus Credit Agreement and Overline Note. The specific nature of the obligation—whether involving a covenant modification, debt restructuring, or other arrangement—cannot be definitively determined without full visibility into the amendment details.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-16
Item 7.01
MSC Industrial announced a cash dividend of $0.87 per share declared by its Board of Directors. While dividend declarations are routine corporate actions, this disclosure is material to investors as it affects shareholder returns and capital allocation. The event does not fit neatly into the more specific taxonomy categories (it is neither an earnings release, executive change, M&A activity, nor a financial restatement), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-16
Item 7.01
SDG&E and SoCalGas filed 2028 General Rate Case applications with the CPUC on June 15, 2026, requesting revenue requirements of $3,760 million (SDG&E) and $5,096 million (SoCalGas) for the 2028 test year, with attrition adjustments through 2031. This is a material regulatory filing that affects authorized revenue recovery and rates, but does not fit neatly into the standard 8-K taxonomy categories. While regulatory decisions are inherently material to utility investors, this disclosure is primarily informational about a pending CPUC proceeding rather than a discrete event like a covenant breach, impairment, or M&A activity.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-16
Item 8.01
The disclosure announces FDA acknowledgment of a BLA resubmission for ONS-5010 (bevacizumab-vikg) with a Class 1 review designation and a 60-day PDUFA goal date of July 29, 2026. This is a material regulatory milestone for a biopharmaceutical company's lead product candidate, but does not fit neatly into the more specific event categories (it is neither a final approval/denial, a going-concern issue, nor a material impairment). The event would affect a reasonable investor's assessment of the company's regulatory progress and near-term catalysts.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-16
Item 5.03
The Company's certificate of incorporation and bylaws were completely amended and restated pursuant to the terms of the Merger Agreement at the Effective Time, reflecting the completed merger transaction.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-16
Item 1.01
Antero Resources established a $1.65 billion commercial paper program on June 16, 2026, creating a material direct financial obligation. The program includes dealer agreements and is intended for general corporate purposes including acquisitions and debt repayment, representing a significant financing commitment affecting the company's liquidity and capital structure.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-16
Item 8.01
The disclosure announces a new patent related to manufacturing of pelareorep and updates to the intellectual property portfolio. For a biotech company, patent issuance and IP portfolio strengthening can be material to investors assessing competitive position and product protection, though the filing provides limited detail on the patent's scope or commercial significance. This does not fit neatly into the more specific event categories (not earnings, litigation, impairment, etc.), warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-16
Item 7.01
The filing discloses a press release highlighting five gene therapy programs targeting inherited retinal diseases. This is a material corporate development disclosure that does not fit neatly into the standard taxonomy categories—it is neither an earnings release, M&A activity, executive change, nor litigation. For a biotech company, disclosure of multiple gene therapy programs represents material pipeline information that would affect investor assessment of the company's prospects and competitive position.
View raw filing on EDGAR →